Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06649812 · ClinicalTrials.gov registry record · Phase 2

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

A Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma and Refractory Diffuse Large B-Cell Lymphoma, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT06649812 is a Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma and Refractory Diffuse Large B-Cell Lymphoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 120 participants, above the 45-participant average among 43 other Recurrent Diffuse Large B-Cell Lymphoma trials with a reported enrollment target (167% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06649812, a Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma and Refractory Diffuse Large B-Cell Lymphoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.

Conditions Studied

Recurrent Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Aspiration
  • PROCEDURE Bone Marrow Biopsy
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy Procedure

Study Locations (20)

Illinois

  • Northwestern University - Chicago
  • Carle at The Riverfront - Danville
  • Northwestern Medicine Cancer Center Kishwaukee - DeKalb
  • Carle Physician Group-Effingham - Effingham
  • Northwestern Medicine Cancer Center Delnor - Geneva
  • Northwestern Medicine Glenview Outpatient Center - Glenview
  • Northwestern Medicine Grayslake Outpatient Center - Grayslake
  • Northwestern Medicine Lake Forest Hospital - Lake Forest
  • Carle Physician Group-Mattoon/Charleston - Mattoon
  • Carle BroMenn Medical Center - Normal
  • Carle Cancer Institute Normal - Normal
  • Northwestern Medicine Oak Brook - Oak Brook

Idaho

  • Kootenai Health - Coeur d'Alene - Coeur d'Alene
  • Kootenai Clinic Cancer Services - Post Falls - Post Falls
  • Kootenai Clinic Cancer Services - Sandpoint - Sandpoint

Arizona

  • Banner University Medical Center - Tucson - Tucson
  • University of Arizona Cancer Center-North Campus - Tucson

Connecticut

  • Smilow Cancer Hospital Care Center - Guilford - Guilford
  • Yale University - New Haven

California

  • Cedars Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-10-07
Est. Completion 2027-09-01
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06649812

The ClinicalTrials.gov registry entry for NCT06649812 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 43 other Recurrent Diffuse Large B-Cell Lymphoma trials with a reported enrollment target (167% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Recurrent Diffuse Large B-Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06649812 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Idaho, Arizona.

Frequently Asked Questions

What is clinical trial NCT06649812 about?

NCT06649812 is a clinical study titled "Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma". This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (rel...

What is the current status of trial NCT06649812?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-10-07. Estimated completion is 2027-09-01.

What conditions does trial NCT06649812 study?

This clinical trial studies the following conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements.

What interventions are being tested in trial NCT06649812?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE).

Who is sponsoring clinical trial NCT06649812?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06649812 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Diffuse Large B-Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Diffuse Large B-Cell Lymphoma

All registered trials for this condition

Refractory Diffuse Large B-Cell Lymphoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.